



SPH.L

Sinclair Pharma plc: Annual Information Update

Sinclair Pharma Plc ("Sinclair" or "the Company": SPH:L), the international specialty pharma company, is required to provide an annual information update in accordance with the requirements of Prospectus Rule 5.2.1R, of information that has been published or made available to the public for the period from 26 November 2009 to date. The information referred to in this update was current at the time the information was published but some information may now be out of date.

1. Announcements made via a Regulatory Information Service

The Company made the following regulatory announcements via the Regulatory News Service on or around the dates indicated:

Date	Announcement
10/11/2010	TR-1: Notification of a major interest in shares
09/11/2010	TR-1: Notification of a major interest in shares
08/11/2010	Interim Management Statement – Return to Growth
29/10/2010	Total Voting Rights
28/10/2010	Notification of a Major Interest in Shares
25/10/2010	Posting of 2010 Annual Report and Notice of AGM
12/10/2010	Grant of Share Awards
08/10/2010	TR-1: Notification of a major interest in shares
08/10/2010	TR-1: Notification of a major interest in shares
07/10/2010	Notification of a Major Interest in Shares
04/10/2010	Result of General Meeting
01/10/2010	Results of the Firm Placing and Placing and Open Offer
27/09/2010	TR-1: Notification of major interest in shares
17/09/2010	Publication of Prospectus
17/09/2010	TR-1: Notification of major interest in shares
13/10/2010	Atopiclair Cream receives reimbursement status in France
09/09/2010	FY Results: Restructuring primes business for growth
07/09/2010	Kelo-Cote licensing deal completed



06/09/2010	Convertible Unsecured Loan Notes
26/08/2010	Proposed Firm Placing and Placing and Open Offer
10/08/2010	Block Listing Six Monthly Return
30/07/2010	Total Voting Rights
16/07/2010	Trading Update – Strong Performance
30/06/2010	Total Voting Rights
03/06/2010	Director/PDMR Shareholding
02/06/2010	Decapinol Agreement
28/05/2010	Director/PDMR Shareholding
25/05/2010	Director/PDMR Shareholding
19/05/2010	Interim Management Statement
05/05/2010	Director/PDMR Shareholding
29/04/2010	Holding(s) in Company
13/04/2010	Holding(s) in Company
31/03/2010	Total Voting Rights
16/03/2010	Holding(s) in Company
25/02/2010	Interim Results
11/02/2010	Notice of Results
10/02/2010	Block Listing Interim Review
13/01/2010	Director Shareholding
22/12/2009	Result of AGM
16/12/2009	Holding(s) in Company
15/12/2009	Total Voting Rights
15/12/2009	Holding(s) in Company
11/12/2009	Sinclair completes Acquisition from Solvay
10/12/2009	Result of General Meeting
10/12/2009	Result of Firm Placing and Open Offer



01/12/2009	Holding(s) in Company
26/11/2009	Annual Report and Notice of AGM
26/11/2009	Annual Information Update

2. Documents filed at Companies House

Type	Date	Description
SH01	21/10/2010	Statement of capital £2,304,585
RES10	13/10/2010	Authorised allotment of shares and debentures
RES13	13/10/2010	Issue of shares approved
CH03	01/06/2010	Change of particulars – Mr Stephen Redman
AP03	19/02/2010	Appointment of Stephen Redman as company secretary
TM02	19/02/2010	Resignation of Alan Olby as company secretary
SH01	12/02/2010	Statement of capital £1,610,790
AA	08/02/2010	Group of companies accounts made up to 30 June 2009
AP01	01/02/2010	Appointment of Christopher Spooner as a director
AR01	14/01/2010	Annual return
AP01	05/01/2010	Appointment of Christophe Foucher as a director
RES13	05/01/2010	Reappointment of a director, auditors and approval of directors remuneration report
RES01	05/01/2010	Alteration to memorandum and articles
RES11	05/01/2010	Disapplication of pre-emption rights
RES09	05/01/2010	Authority to purchase shares other than from capital
RES10	05/01/2010	Authorised allotment of shares and debentures
TM01	05/01/2010	Resignation of Michael Flynn as a director
RES04	20/12/2009	Increase in nominal capital to £2,000,000
RES11	20/12/2009	Disapplication of pre-emption rights
RES10	20/12/2009	Authorised allotment of shares and debentures



RES13	20/12/2009	Proposed acquisition approved
TM01	15/12/2009	Resignation of Jeremy Randall as a director

Copies of documents filed at Companies House can be obtained from the Companies House website at www.companieshouse.gov.uk or Companies House, Crown Way, Cardiff F14 3UZ.

3. Additional Documents

The Company submitted copies of the following documents to the UK Listing Authority, which have also been provided to shareholders:

Date	Document
25/10/2010	Annual report and accounts for the year ended 30 June 2010 and Notice of Annual General Meeting
17/09/2010	Prospectus in relation to firm placing and open offer of 67,857,131 new ordinary shares at 28 pence per new ordinary share and Notice of General Meeting
25/02/2010	Interim report for the six months to 31 December 2009

All of the documents listed above can be obtained from the Company's website www.sinclairpharma.com and have been submitted to the National Storage Mechanism available at www.hemscott.com/nsm.do.

- Ends -

For further information please contact:

Sinclair Pharma plc
Chris Spooner, CEO
Alan Olby, CFO

Tel: +44 (0)1483 410 600

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång

Tel: +44 (0)20 3205 7500

Biddicks, Financial Public Relations
Shane Dolan

Tel: +44 (0)20 7448 1000

Notes to Editors:

About Sinclair Pharma Plc www.sinclairpharma.com

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and



innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed & emerging markets.

This annual information update is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented in the UK by Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Further, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to in it, constitutes, by virtue of this communication, an offer of any securities addressed to any person and it should not be relied on by any person.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.